Positive dupixent® (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 aaaai annual meeting

Tarrytown, n.y. and paris, feb. 1, 2022 /prnewswire/ -- late-breaking pivotal data show significant disease improvements in eosinophilic esophagitis and also in chronic spontaneous urticaria 18 abstracts add to body of evidence that il-4 and il-13 pathways inhibited by dupixent are key drivers of the type 2 inflammation underlying certain diseases, accounting for the impact of dupixent in its approved and investigational indications regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced positive dupixent® (dupilumab) data across five diseases with underlying type 2 inflammation will be presented at the american academy of allergy, asthma and immunology (aaaai) annual meeting from february 25 to 28.
REGN Ratings Summary
REGN Quant Ranking